3^rd Biomedical Engineering and Expo

Biography

Dr. Guertin has 27 years of experience in spinal cord research and 15 years of experience in science leadership. He was President and CEO of NeuroSpina Therapeutics between 2005 and 2008 and Chief Scientific Officer of Eurymedon HealthCare during the same period. Over the years, he has obtained 4.6 million dollars in financing from not-for-profit public agencies and private foundations to conduct fundamental research in rodents, drug development and clinical studies. He has developed a cutting-edge expertise in spinal cord injury and aging, metabolic problems, urogenital and bowel problems, and musculoskeletal and skin degradation. In addition to his current position as President and CEO of Nordic Life Science Pipeline, he holds also positions as Full Professor in the Department of Psychiatry & Neurosciences at Université Laval (2001 - present) and as of Director/Principal Investigator of the Spinal Cord Injury and Functional Recovery Laboratory (2002 - present) based in Québec City (Laval University Medical Center – CHU de Québec). As a leading scientist, he is author and co-author of more than 100 publications (articles, reviews, book chapters, patents, etc.) since 1990. He acts also as editorial board member, referee and reviewer for several biomedical journals and North American granting agencies such as CIHR, NSERC, FRSQ, and CDMRP.

Research Interest

Prof. Dr. Guertin has been exploring for 30 years the physiology of motor control and movement. He spent 27 years specifically studying the neurological system and 15 years in science leadership positions as academic laboratory director and executive (CEO, CSO, COO) for several biopharmaceutical companies. He developed a cutting-edge expertise in spinal cord injury, aging, metabolic, urogenital, bowel, musculoskeletal and skin problems. As an inventor and serial entrepreneur, he is passionate about preclinical, clinical and business development, from bench-to-bedside, of first-in-class medicines for people with paralysis and mobility impairment due to disease or aging. His extensive hands-on multidisciplinary experience in drug discovery and development shall also serve other key players of that ecosystem such as venture capital firms, investment banks, tech-transfer organizations, patent firms and biopharmaceutical companies towards his main goal - that is improving healthcare worldwide through approval of new gold-standard medicines for significant unmet medical needs.